Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E. Kylin.
Studies of the hypertension-hyperglycemia-hyperuricemia syndrome.
Zentral-Blatt Fuer Innere Medizin, 44 (1923), pp. 105-127
[2.]
G.M. Reaven.
Banting lecture 1988 Role of insulin resistance in human disease.
Diabetes, 37 (1988), pp. 1595-1607
[3.]
G.M. Reaven.
The metabolic syndrome or the insulin resistance syndrome?.
Different names, different concepts, and different goals. Endocrinol Metab Clin North Am, (2004), pp. 283-303
[4.]
K. Alberti, P. Zimmet.
for a WHO Consultation. Diagnosis and Classification of Diabetes Mellitus.
Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications,
[5.]
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
JAMA, 285 (2001), pp. 2486-2497
[6.]
G. Hu, Q. Qiao, J. Tuomilehto, B. Balkau, K. Borch-Johnsen.
Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.
Arch Intern Med, 164 (2004), pp. 1066-1076
[7.]
B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, et al.
Cardiovascular morbidity and mortality associated with the metabolic syndrome.
Diabetes Care, 24 (2001), pp. 683-689
[8.]
E.S. Ford, W.H. Giles.
A comparison of the prevalence of the metabolic syndrome using two proposed definitions.
Diabetes Care, 26 (2003), pp. 575-581
[9.]
H.M. Lakka, D.E. Laaksonen, T.A. Lakka, L.K. Niskanen, E. Kumpusalo, J. Tuomilehto, et al.
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.
JAMA, 288 (2002), pp. 2709-2716
[10.]
E.S. Ford.
The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study.
Atherosclerosis, 173 (2004), pp. 309-314
[11.]
J.L. Anderson, B.D. Horne, H.U. Jones, S.P. Reyna, J.F. Carlquist, T.L. Bair.
et al; Intermountain Heart Collaborative (IHC) Study. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?.
Cardiology, 101 (2004), pp. 185-193
[12.]
K.E. Kip, O.C. Marroquin, D.E. Kelley, B.D. Johnson, S.F. Kelsey, L.J. Shaw, et al.
Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study.
Circulation, 109 (2004), pp. 706-713
[13.]
E. Bonora, S. Kiechl, J. Willeit, F. Oberhollenzer, G. Egger, R.C. Bonadonna, et al.
Bruneck study. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study.
Diabetes Care, 26 (2003), pp. 1251-1257
[14.]
G. Marchesini, G. Forlani, F. Cerrelli, R. Manini, S. Natale, L. Baraldi, et al.
WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes.
Diabet Med, 21 (2004), pp. 383-387
[15.]
J. Vidal, R. Morínigo, L. Rodríguez, V. Moizé, V.H. Codoceo, R. Casamitjana.
Criterios diagnósticos de síndrome metabólico y enfermedad cardiovascular en pacientes adultos obesos.
Endocrinol Nutr, 51 (2004), pp. 1
[16.]
D.A. Lawlor, S. Ebrahim, G. Davey Smith.
The metabolic syndrome and coronary heart disease in older women: findings from the British Women's Heart and Health Study.
Diabet Med, 21 (2004), pp. 906-913
[17.]
S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, M. Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med, 339 (1998), pp. 229-234
[18.]
A. Ceriello.
Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia.
Am Heart J, 147 (2004), pp. 803-807
[19.]
G. Schillaci, M. Pirro, G. Vaudo, F. Gemelli, S. Marchesi, C. Porcellati, et al.
Prognostic value of the metabolic syndrome in essential hypertension.
J Am Coll Cardiol, 43 (2004), pp. 1817-1822
[20.]
Y.W. Park, S. Zhu, L. Palaniappan, S. Heshka, M.R. Carnethon, S.B. Heymsfield.
The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994.
Arch Intern Med, 163 (2003), pp. 427-436
[21.]
L.T. Clark, K.C. Ferdinand, J.M. Flack, Gavin Jr, W.D. Hall, S.K. Kumanyikz, et al.
Coronary heart disease in African Americans.
Heart Dis, 3 (2001), pp. 97-108
[22.]
C.D. Stehouwer, M.A. Gall, J.W. Twisk, E. Knudsen, J.J. Emeis, H.H. Parving.
Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death.
Diabetes, 51 (2002), pp. 1157-1165
[23.]
A.J. Hanley, L.E. Wagenknecht, J.r. D'Agostino RB, B. Zinman, S.M. Haffner.
Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome.
Diabetes, 52 (2003), pp. 2740-2747
[24.]
S.A. Hills, B. Balkau, S.W. Coppack, J.M. Dekker, A. Mari, A. Natali.
et al; EGIR-RISC Study Group. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives.
Diabetologia, 47 (2004), pp. 566-570
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
